Original language | English |
---|---|
Pages (from-to) | S1164-S1165 |
Number of pages | 2 |
Journal | Annals of Oncology |
Volume | 31 |
DOIs | |
Publication status | Published - Sept 2020 |
Event | ESMO Virtual Congress 2020 - , Virtual Duration: 19 Sept 2020 → 21 Sept 2020 |
Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials
D. M. O'Malley, A. Oaknin, B. J. Monk, A. Leary, F. Selle, J. Alexandre, L. M. Randall, C. Rojas, M. Neffa, A. Kryzhanivska, L. Gladieff, D. Berton, T. Meniawy, I. Lugowska, I. Bondarenko, K. N. Moore, W. I. Ortuzar Feliu, M. Ancukiewicz, I. Shapiro, I. L. Ray-Coquard
Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review
29
Citations
(Web of Science)